Disclosures Dr Mosnaim receives current research grant support from Areteia, GlaxoSmithKline, Genentech, Incyte, Novartis, Sanofi-Regeneron, and Teva; and receives consulting, advisory board, and/or speaking fees from Chiesi, Genentech, Novartis, Sanofi-Regeneron, and Teva. Dr Anagnostou reports receiving institutional funding from Aquestive and Novartis and personal fees (consultation and speaker services) from Ready. Set. Food!, Novartis, Genentech, Medscape, Stallergens, ARS, and FARE. Dr Greenhawt serves as chief medical officer for the Asthma and Allergy Foundation of America; serves as a consultant for Aquestive; is a speaker for ARS and Genentech; serves as an advisory board member for Aquestive, ALK-Abello, AllergyTherapeutics, AstraZeneca, Bryn Pharma, DBV Technologies, Novartis, Nutricia, and Prota; is an unpaid member of the scientific advisory council for the National Peanut Board, the medical advisory board of the International Food Protein Induced Enterocolitis Syndrome Association, and the Medical Science Council for the Asthma and Allergy Foundation of America; serves as a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group; is the senior associate editor for the Annals of Allergy, Asthma and Immunology; and is a member of the Joint Task Force on Allergy Practice Parameters. Dr Shaker is a member of the Joint Task Force on Practice Parameters; serves on the editorial board of The Journal of Allergy and Clinical Immunology In Practice; is an associate editor of Annals of Allergy, Asthma and Immunology; and serves on the board of directors of the American Academy of Allergy, Asthma, and Immunology (views expressed are his own). Dr Taylor-Black has no conflicts of interest to report.